Clinical and therapeutic behaviour of fasciola hepatica in a series of 87 patients;Comportamiento clínico-terapéutico de fasciola hepatica en una serie de 87 pacientes

Revista Cubana de Medicina Tropical

Volumn 63, Issue 3, 2011, Pages 268-274

  Fernández, René Díaz ^a   Martínez, Madelyn Garcés ^a   Álvarez, Leslie M Millán ^a   Lastre, Jorge Pérez ^a   Marcelo, Juan Carlos Millán ^a  

^a INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

Abdominal pain; Dihydroemetine; Fasciola hepatica; Triclabendazole

Indexed keywords

EID: 80755152915     PISSN: 03750760     EISSN: 15613054     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Mandell GL, Bennett JE, Dolin R. Principles and Practice of Infectious Diseases. 6th Edition; 2005. p. 3282. Bookmark. Available in: http:www/dos/book/view/58590031-2/1259/2562.htlm/top
2. Devine C, Brennan GP, Lanusse CE, Alvarez LI, Trudgett A, Hoey E, et al. Piperonyl butoxide enhances triclabendazole action against triclabendazole-resistant Fasciola hepatica. 2011;138(2):224-36.
3. Duthaler U, Smith TA, Keiser J. In vivo and in vitro sensitivity of Fasciola hepatica to triclabendazole combined with artesunate, artemether, or OZ78. Antimicrob Agents Chemother. 2010;54(11):4596-604.
4. Millán AM, Wagenknecht SR, Cárdenas PA, Carrasco LC. Parásitos de fasciola hepática intracoledociano. Rev Chil Cir. 2008;60(4):332-5. Disponible en: http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0718-40262008000400012&lng=es. doi: 10.4067/S0718-40262008000400012
5. Keshishian J, Brantley SG, Brady PG. Biliary fascioliasis mimicking sphincter of Oddi dysfunction. South Med J. 2010;103(4):366-8.
6. Espino AM, Borges A, Dumenigo BE. Coproantígenos de Fasciola hepatica de posible utilidad en el diagnóstico de la fasciolosis. Rev Panam Salud Pública. 2000;7(4):225-31.
7. Kouri P. Helmintología Humana. Tomo I. 3ra edición. La Habana; 1977. p. 570-616.
8. Mas-Coma S. Human fascioliasis: epidemiological patterns in human endemic areas of South America, Africa and Asia. Southeast Asian J Trop Med Public Health. 2004;35:1-11.
9. Favennec L, Ortiz Jave J, Gargala G, Lopez Chegne N, Ayoub A, Rossignol JF. Double-blind randomized placebo controlled study of nitaxozanide in the treatment of fascioliasis in adults and children from northern Peru. Aliment Pharmacol Ther. 2003;17:265-70.
10. Marcos Luis A, Tagle M, Terashima A, Bussalleu A, Ramírez C, Carrasco C, et al. Natural history, clinicoradiologic correlates, and response to triclabendazole in acute massive fascioliasis. Am J Trop Med Hyg. 2008;78(2):222-7.
11. Chand M, Hermann JS, Partridge DG, Hewitt K, Chiodini PL. Imported human fasciolasis, United Kingdom. Emerg Infect Dis. 2009;5(11):1876-7.
12. Lim JH, Mairiang E, Ahn GH. Biliary parasitic diseases including clonorchiasis, opisthorchiasis and fascioliasis. Abdom Imaging. 2008;33(2):157-65.
13. Keiser J, Utzinger J. Food-borne trematodiases. Clin Microbiol Rev. 2009;22(3):466-83.
14. Tinh T, Thanh N, Hoan N, Dinh H, Nguyen TD, Nguyen TH, et al. A Randomized controlled pilot study of Artesunate versus Triclabendazole for human fascioliasis in Central Vietnam. Am J Trop Med Hyg. 2008;78(3):388-92.
15. Parkinson M, O'Neill SM, Dalton JP. Endemic human fascioliasis in the Bolivian Altiplano. Epidemiol Infect. 2007;135(4):169-74.
16. Rojas L, Vazquez A, Domenech I, Robertson L. Fascioliasis: can Cuba conquer this emerging parasitosis?. Trends Parasitol. 2010;26(1):26-34.
17. Cosme A, Ojeda E, Cilla G, Torrado J, Alzate L, Beristain X, et al. Fasciola hepatica: study of a series of 37 patients. Gastroenterol Hepatol. 2001;24(8):375-80.
18. Demirci M, Korkmaz M, Kaya S, Kuman A. Fascioliasis in eosinophilic patients in the Isparta Region of Turkey. Infection. 2003;31:15-8.
19. Farag HF. Human fascioliasis in some countries of the Eastern Mediterranean Region. East Mediterr Health J. 1998;4(1):156-60.
20. Censo de Población y Viviendas Cuba 2002. Informe Nacional de la Oficina Nacional de Estadísticas. Disponible en: http://www.cubagob.cu/otras_info/censo/tablas_pdf/informe_nacional.pdf
21. Pérez A, Casero T, Martínez R, Pérez O. Aspectos epidemiológicos sobre Fasciola hepatica. Rev Cubana Med Trop. 1986;38(3):263-9.
22. Bargues MD, Mas Coma S. Reviewing lymnaeid vectors of fascioliasis by ribosomal DNA sequence analyses. J Helminthol.2005;79:257-67.
23. Barcat JA. El berro y otras comidas peligrosas. Medicina (Buenos Aires). 2005;65:277-9.
24. Chen MG, Mott KE. Progress in assessment of morbidity due to Fasciola hepatica infection: a review of recent literature. Trop Dis Bull. 1990;87:1-38.
25. Mas-Coma S, Esteban JG, Bargues MD. Epidemiología de la fascioliasis humana: revisión y propuesta de nueva clasificación. Bull World Health Org. 1999;77(4):340-6.
26. Mas-Comas S, Valero MA, Bargues MD. Charpter 2. Fasciola, lymnaeids and human fascioliasis, with a global overview on disease transmisión, epidemiology, evolutionary genetics, molecular epidemiology and control. Adv Parasitol. 2009;69:41-146.
27. Caballero Pozo RI. Caracterización clínica de un brote de Fasciola hepatica humana en La Palma, Pinar del Río [Tesis de Maestría]. Ciudad de La Habana: IPK; 1996.
28. Marcos L, Maco V, Terashima A, Salmavides F, Espinoza JR, Gotuzzo E. Fascioliasis in relatives of patients with Fasciola hepatica infection in Peru. Rev Inst Med Trop Sao Paulo. 2005;47(4):219-22.
29. Osman M, Bach-Lausten S, El-Sefi T, Boghdadi I, Rashed MY, Jensen SL. Biliary parasite: a review. Dig Surg. 1998;15:287-96.
30. Rodríguez ME, Díaz A, Martínez R, Millán JC, Ruiz A, Pérez JP. Urticaria y Fasciola hepatica. Rev Cubana Med Trop. 1986;38(3):305-10.
31. Díaz R, González D, Millán LM, Garcés M, Mederos RL, Millán JC. Ictero obstructivo, Fasciola hepatica: presentación de un nuevo caso. Rev Cubana Med Trop. 2005;57(2):152-3.
32. Millan JC, Mull R, Freise S, Ritchter J. The efficacy and tolerability of triclabendazole in Cuban patients with latent and chronic Fasciola hepatica infection. Am J Trop Med Hyg. 2000;63(5-6):264-9.
33. Report of the WHO Informal Meeting on use of triclabendazole in fascioliasis control. Geneva: WHO; 2007. WHO/ CDS/ NTD/ PCT/ 2007.1
34. Keiser J, Engels D, Buscher G, Utzinger J. Triclabendazole of fascioliasis and paragonimiasis. Expert Opin Investig Drugs. 2005;14(12):1513-26.
35. Keiser J, Gruyer MS, Perrottet N, Zanolari B, Mercier T, Decosterd L. Pharmacokinetic parameters of artesunate and dihydroartemisinin in rats infected with Fasciol hepatica. J Antimicrob Chemother. 2009;63:543-9.
36. Brennan GP, Fairweather I, Trudgett A, Hoey E, McCoy, McConville M, et al. Understanding triclabendazole resistance. Exp Mol Pathol. 2007;82(2):104-9.